All In Biotech

Drug Trial Radar · NCT03433898

This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer

An Open Label, Phase I Study of BI 754091 Monotherapy and Combination Therapy of BI 754091 and BI 754111 in Asian Patients With Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

146

Actual

Start

Feb 23, 2018

Primary completion

Jul 20, 2023

Study completion Jul 20, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 15, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objectives of the BI 754091 monotherapy dose-finding part (Part I) of the trial are to investigate the following items in advanced solid tumours: * Safety, tolerability, and pharmacokinetics (PK) of BI 754091 as monotherapy. * Maximum tolerated dose (MTD) and/or recommended dose (RD) of BI 754091 monotherapy. The main objectives of the Combination dose-finding part (Part II) of the trial are to investigate the following items in advanced solid tumours: * Safety, tolerability, and PK of the combination treatment of BI 754091 and BI 754111. * MTD and/or RD of the combination treatment of BI 754091 and BI 754111. The main objectives of the expansion part (Part III) of the trial are: * To further investigate the safety, tolerability, and PK of the RD of BI 754091 and BI 754111 combination in patients with gastric/esophagogastric junction cancer, esophageal cancer, hepatocellular cancer or non-small cell lung cancer (NSCLC) * To explore the efficacy of the RD of the combination of BI 754091 and BI 754111 in patients with gastric/esophagogastric junction cancer, esophageal cancer, hepatocellular cancer or NSCLC

Conditions

  • Neoplasms

Interventions

  • EzabenlimabDrug

    Solution for infusion

  • BI 754111Drug

    Solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part I: Maximum Tolerated Dose (MTD) of EzabenlimabTime frame: First cycle of treatment: 3 weeks (21 days) following drug administration.
  2. Part I: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment)Time frame: First cycle of treatment: 3 weeks (21 days) following drug administration.
  3. Part II: MTD of the Ezabenlimab Plus BI 754111 Combination TherapyTime frame: First cycle of treatment: 3 weeks (21 days) following drug administration.
  4. Part II: Number of Patients Experiencing DLTs During the MTD Evaluation Period (First Cycle of Treatment)Time frame: First cycle of treatment: 3 weeks (21 days) following drug administration.
  5. Part III: Number of Patients With Objective Response (OR) - Confirmed Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 as Assessed by the InvestigatorTime frame: From the date of the first administration of trial treatment until the date of the last administration of trial treatment + 30 days (residual effect period): up to 49 months.

Locations

13 sites in 3 countries. Site status is shown where the registry gives one.

  • National Cancer Center Hospital East

    Chiba, Kashiwa, Japan

  • Kanagawa Cancer Center

    Kanagawa, Yokohama, Japan

  • Saitama Cancer Center

    Saitama, Kitaadachi-gun, Japan

  • Shizuoka Cancer Center

    Shizuoka, Sunto-gun, Japan

  • National Cancer Center Hospital

    Tokyo, Chuo-ku, Japan

  • Japanese Foundation for Cancer Research

    Tokyo, Koto-ku, Japan

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • NCKUH

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Chang Gung Memorial Hospital(Linkou)

    Taoyuan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.